Evogene Ltd Ord (EVGN)

$0.55 +0.02 (3.12%)
Market Cap 4.79M
Revenue (ttm) 3.85M
Net Income (ttm) -8.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -220.52%
Debt to Equity Ratio 0.00
Volume 409,838
Avg Vol 2,108,074
Day's Range N/A - N/A
Shares Out 8.72M
Stochastic %K 40%
Beta 1.40
Analysts Strong Buy
Price Target $2.15

Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commerci...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 931 1900
Fax: 972 8 946 6724
Address:
13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel
ikerrr
ikerrr Jul. 21 at 5:32 PM
$EVGN Looks Like a proxy fight, thats never good short term . Typical bullshit selling at 40 cent ATM prices for AI Tech Pharma crazy. I say get rid of them all, Firesale this POS for $3 ashare or we're looking at R/S. Its they're fault we're at this point F em
0 · Reply
FinacialSuicide
FinacialSuicide Jul. 21 at 1:11 AM
$EVGN
0 · Reply
StockScanners
StockScanners Jul. 18 at 8:33 AM
$EVGN keep watch if this holds above .60
0 · Reply
FinacialSuicide
FinacialSuicide Jul. 17 at 4:25 PM
$EVGN wants to fly higher!
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 17 at 2:26 PM
$EVGN hourly breakout
0 · Reply
suntanner20
suntanner20 Jul. 17 at 11:38 AM
$EVGN Activist investor Silberman took a 1.6m -1.9m stake in Evogene and wants to replace 3 board members with his own people. Incredibly, he wants to keep Ofer Haviv, CEO. The stake is over 10% so he cant sell without filing and if he sells he cant keep profits This stock should scream to 1.25 per share ( armistice 5m warrant price). The float is tight. The validation of Evogene's ChemPass AI should be at record highs for them and industry Pharma ag and tech companies are surrounding it. AI Drug discovery engines are IPOing at 1-2 billion per company. This engine is a 100-200m engine today but being totally mishandled by CEO and board in their capital structure dealings with Armistice and banker AGP. We should be trading at 10 now not .58 that said, the valuation with all the games should be 1.25 Activist if bad actor will take company over and sell chempass for 100m and place new company in shell. If good actor, he'll find a way to drive value in chempass and drive share price up
0 · Reply
StockScanners
StockScanners Jul. 17 at 4:51 AM
$EVGN reached .60
0 · Reply
FinacialSuicide
FinacialSuicide Jul. 16 at 2:47 PM
$EVGN wants to fly! We need help!
0 · Reply
StockScanners
StockScanners Jul. 16 at 4:20 AM
$EVGN keep watch if this holds above .49
0 · Reply
MrTicker
MrTicker Jul. 15 at 11:38 AM
$EVGN Evogene's AgPlenus Subsidiary Introduces Antifungal Potency Predictor BENZINGA 6:33 AM ET 7/15/2026 AgPlenus Ltd., a company developing novel, sustainable crop protection products and a subsidiary of Evogene Ltd.(EVGN) , today announced the launch of its Antifungal Potency Predictor (APP). This new machine learning model predicts the antifungal potency of small molecules directly from their chemical structures, expanding the capabilities of Evogene's(EVGN) ChemPass AI for Ag™ platform by forecasting biological efficacy prior to chemical synthesis and fungal assay validation.
0 · Reply
Latest News on EVGN
Evogene and ELEO announce scientific collaboration

2026-07-22T12:06:12.000Z - 8 hours ago

Evogene and ELEO announce scientific collaboration

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

Wed, 22 Jul 2026 08:00:00 -0400 - 9 hours ago

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities

Wed, 15 Jul 2026 07:30:00 -0400 - 7 days ago

AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities

Evogene (EVGN) Partners with Tel Aviv University for Drug Discovery Innovation

2026-07-08T12:28:10.000Z - 14 days ago

Evogene (EVGN) Partners with Tel Aviv University for Drug Discovery Innovation

Evogene, BCDD announces strategic joint initiative

2026-07-08T11:11:22.000Z - 14 days ago

Evogene, BCDD announces strategic joint initiative

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Wed, 08 Jul 2026 07:00:00 -0400 - 14 days ago

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Evogene (EVGN) Achieves Milestone in Collaboration with Google Cloud

2026-06-24T13:29:04.000Z - 4 weeks ago

Evogene (EVGN) Achieves Milestone in Collaboration with Google Cloud

Evogene achieves integration of agentic systems with ChemPass AI platform

2026-06-24T12:10:55.000Z - 4 weeks ago

Evogene achieves integration of agentic systems with ChemPass AI platform

GOOG GOOGL

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

Wed, 24 Jun 2026 08:00:00 -0400 - 4 weeks ago

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

Evogene Slides: Company presentation

Jun 16, 2026, 7:00 AM EDT - 5 weeks ago

Evogene Slides: Company presentation

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Tue, 09 Jun 2026 07:00:00 -0400 - 6 weeks ago

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results

2026-06-02T12:34:46.000Z - 7 weeks ago

Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results

Evogene says Phase 1 clinical study of BMC128 met primary endpoint

2026-06-02T11:06:21.000Z - 7 weeks ago

Evogene says Phase 1 clinical study of BMC128 met primary endpoint

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Tue, 02 Jun 2026 07:00:00 -0400 - 7 weeks ago

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene price target lowered to $2.15 from $2.25 at Alliance Global

2026-05-26T19:10:13.000Z - 2 months ago

Evogene price target lowered to $2.15 from $2.25 at Alliance Global

Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected

2026-05-20T14:42:55.000Z - 2 months ago

Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected

Evogene Earnings Call Transcript: Q1 2026

May 20, 2026, 9:00 AM EDT - 2 months ago

Evogene Earnings Call Transcript: Q1 2026

Evogene Earnings release: Q1 2026

May 20, 2026, 9:00 AM EDT - 2 months ago

Evogene Earnings release: Q1 2026

Evogene (EVGN) Reports Decrease in Q1 Revenue Amid Strategic Transformation

2026-05-20T12:29:49.000Z - 2 months ago

Evogene (EVGN) Reports Decrease in Q1 Revenue Amid Strategic Transformation

Evogene reporta Q1 cont. ops. EPS (60c) vs. (26c) last year

2026-05-20T11:11:26.000Z - 2 months ago

Evogene reporta Q1 cont. ops. EPS (60c) vs. (26c) last year

Evogene Reports First Quarter 2026 Financial Results

Wed, 20 May 2026 07:00:00 -0400 - 2 months ago

Evogene Reports First Quarter 2026 Financial Results

Evogene to Present at the 24th Schrödinger European User Group Meeting

Tue, 12 May 2026 08:00:00 -0400 - 2 months ago

Evogene to Present at the 24th Schrödinger European User Group Meeting

Evogene Schedules First Quarter 2026 Financial Results Release

Thu, 07 May 2026 08:00:00 -0400 - 2 months ago

Evogene Schedules First Quarter 2026 Financial Results Release

Evogene price target raised to $2.25 from $1.75 at Alliance Global

2026-04-13T14:21:10.000Z - 3 months ago

Evogene price target raised to $2.25 from $1.75 at Alliance Global

Evogene (EVGN) Faces Nasdaq Compliance Challenge Over Bid Price

2026-04-02T21:27:08.000Z - 3 months ago

Evogene (EVGN) Faces Nasdaq Compliance Challenge Over Bid Price

Evogene receives Nasdaq minimum bid price notification

2026-04-02T20:05:46.000Z - 3 months ago

Evogene receives Nasdaq minimum bid price notification

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Thu, 02 Apr 2026 16:01:00 -0400 - 3 months ago

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Tue, 31 Mar 2026 08:00:00 -0400 - 4 months ago

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Evogene files to sell 5.08M ordinary shares for holders

2026-03-26T20:35:48.000Z - 4 months ago

Evogene files to sell 5.08M ordinary shares for holders

Evogene Registration statement: Registration filing

Mar 26, 2026, 8:00 AM EDT - 4 months ago

Evogene Registration statement: Registration filing

Evogene price target lowered to $1.75 from $2.50 at Alliance Global

2026-03-13T15:40:44.000Z - 4 months ago

Evogene price target lowered to $1.75 from $2.50 at Alliance Global

Evogene Slides: Corporate presentation

Mar 12, 2026, 8:00 AM EDT - 4 months ago

Evogene Slides: Corporate presentation

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Mon, 09 Mar 2026 09:00:00 -0400 - 4 months ago

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Evogene Earnings Call Transcript: Q4 2025

Mar 5, 2026, 9:00 AM EST - 4 months ago

Evogene Earnings Call Transcript: Q4 2025

Evogene Annual report: Q4 2025

Mar 5, 2026, 9:00 AM EST - 4 months ago

Evogene Annual report: Q4 2025

Evogene Quarterly report: Q4 2025

Mar 5, 2026, 9:00 AM EST - 4 months ago

Evogene Quarterly report: Q4 2025

Evogene (EVGN) Focuses on Key Markets Following Strategic Shift

2026-03-05T12:41:07.000Z - 4 months ago

Evogene (EVGN) Focuses on Key Markets Following Strategic Shift

Evogene Earnings Review: Q4 Summary

2026-03-05T12:10:35.000Z - 4 months ago

Evogene Earnings Review: Q4 Summary

Evogene reports Q4 cont ops EPS (61c) vs. 17c last year

2026-03-05T12:09:46.000Z - 4 months ago

Evogene reports Q4 cont ops EPS (61c) vs. 17c last year

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

Thu, 05 Mar 2026 07:00:00 -0500 - 4 months ago

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

An Overview of Evogene's Earnings

2026-03-04T19:01:57.000Z - 5 months ago

An Overview of Evogene's Earnings

Evogene Releases CEO Letter to Shareholders

Wed, 25 Feb 2026 08:00:00 -0500 - 5 months ago

Evogene Releases CEO Letter to Shareholders

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Thu, 19 Feb 2026 08:00:00 -0500 - 5 months ago

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Evogene (EVGN) Partners with QUT to Combat Lung Cancer Drug Resistance

2026-02-17T13:33:51.000Z - 5 months ago

Evogene (EVGN) Partners with QUT to Combat Lung Cancer Drug Resistance

Evogene collaborates with Queensland University in AI-driven cancer therapeutics

2026-02-17T13:10:12.000Z - 5 months ago

Evogene collaborates with Queensland University in AI-driven cancer therapeutics

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Tue, 17 Feb 2026 08:00:00 -0500 - 5 months ago

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Wed, 11 Feb 2026 08:00:00 -0500 - 5 months ago

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

Tue, 10 Feb 2026 13:20:00 -0500 - 5 months ago

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

Evogene (EVGN) Expands Collaboration with Google Cloud to Boost AI Capabilities

2026-02-10T13:29:55.000Z - 5 months ago

Evogene (EVGN) Expands Collaboration with Google Cloud to Boost AI Capabilities

Evogene expands collaboration with Google Cloud for AI agents into ChemPass AI

2026-02-10T13:16:48.000Z - 5 months ago

Evogene expands collaboration with Google Cloud for AI agents into ChemPass AI

GOOG GOOGL

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Tue, 10 Feb 2026 08:00:00 -0500 - 5 months ago

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Evogene Appoints Prof. John Irwin and Prof.

Mon, 09 Feb 2026 08:00:00 -0500 - 5 months ago

Evogene Appoints Prof. John Irwin and Prof.

Evogene, Shanghai Lishan Biopharmaceuticals enter BMC128 licensing agreement

2026-02-05T11:00:14.000Z - 5 months ago

Evogene, Shanghai Lishan Biopharmaceuticals enter BMC128 licensing agreement

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Wed, 04 Feb 2026 22:00:00 -0500 - 5 months ago

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Biomica and Lishan Biotech sign licensing agreement for BMC128

2026-02-04T13:05:13.000Z - 6 months ago

Biomica and Lishan Biotech sign licensing agreement for BMC128

Evogene, Unravel Biosciences announce scientific collaboration

2026-01-07T12:15:13.000Z - 7 months ago

Evogene, Unravel Biosciences announce scientific collaboration

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Wed, 07 Jan 2026 07:00:00 -0500 - 7 months ago

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Evogene appoints Nissan as VP of Business Development

2025-12-30T12:10:49.000Z - 7 months ago

Evogene appoints Nissan as VP of Business Development

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Tue, 30 Dec 2025 07:00:00 -0500 - 7 months ago

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Evogene Earnings Call Transcript: Q3 2025

Nov 20, 2025, 9:00 AM EST - 8 months ago

Evogene Earnings Call Transcript: Q3 2025

Evogene Quarterly report: Q3 2025

Nov 20, 2025, 9:00 AM EST - 8 months ago

Evogene Quarterly report: Q3 2025

Evogene Reports Third Quarter 2025 Financial Results

Thu, 20 Nov 2025 07:00:00 -0500 - 8 months ago

Evogene Reports Third Quarter 2025 Financial Results

Evogene’s Casterra and Fantini announce strategic collaboration

2025-11-11T12:11:04.000Z - 9 months ago

Evogene’s Casterra and Fantini announce strategic collaboration

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Tue, 11 Nov 2025 07:00:00 -0500 - 9 months ago

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Evogene Schedules Third Quarter 2025 Financial Results Release

Thu, 06 Nov 2025 09:00:00 -0500 - 9 months ago

Evogene Schedules Third Quarter 2025 Financial Results Release

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Aug 28, 2025, 7:00 AM EDT - 11 months ago

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Evogene Earnings Call Transcript: Q2 2025

Aug 19, 2025, 9:00 AM EDT - 1 year ago

Evogene Earnings Call Transcript: Q2 2025

Evogene Quarterly report: Q2 2025

Aug 19, 2025, 9:00 AM EDT - 1 year ago

Evogene Quarterly report: Q2 2025

Evogene Reports Second Quarter 2025 Financial Results

Aug 19, 2025, 7:00 AM EDT - 1 year ago

Evogene Reports Second Quarter 2025 Financial Results

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Evogene Schedules Second Quarter 2025 Financial Results Release

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Evogene Schedules Second Quarter 2025 Financial Results Release

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

ICL

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

Evogene Slides: Company Presentation

Jun 1, 2025, 6:00 AM EDT - 1 year ago

Evogene Slides: Company Presentation

Evogene Earnings Call Transcript: Q1 2025

May 21, 2025, 9:00 AM EDT - 1 year ago

Evogene Earnings Call Transcript: Q1 2025

Evogene Quarterly report: Q1 2025

May 21, 2025, 9:00 AM EDT - 1 year ago

Evogene Quarterly report: Q1 2025

Evogene Reports First Quarter 2025 Financial Results

May 21, 2025, 7:00 AM EDT - 1 year ago

Evogene Reports First Quarter 2025 Financial Results

Evogene Schedules First Quarter 2025 Financial Results Release

May 8, 2025, 7:00 AM EDT - 1 year ago

Evogene Schedules First Quarter 2025 Financial Results Release

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Apr 21, 2025, 7:00 AM EDT - 1 year ago

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Evogene Earnings Call Transcript: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Earnings Call Transcript: Q4 2024

Evogene Annual report: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Annual report: Q4 2024

Evogene Earnings release: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Earnings release: Q4 2024

Evogene Slides: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Slides: Q4 2024

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 7:15 AM EST - 1 year ago

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Mar 6, 2025, 7:00 AM EST - 1 year ago

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Feb 20, 2025, 7:00 AM EST - 1 year ago

Evogene Schedules Fourth Quarter 2024 Financial Results Release

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Feb 13, 2025, 8:00 AM EST - 1 year ago

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Evogene Slides: Company Presentation

Dec 19, 2024, 7:00 AM EST - 1 year ago

Evogene Slides: Company Presentation

Evogene Slides: Corporate Presentation

Nov 28, 2024, 7:00 AM EST - 1 year ago

Evogene Slides: Corporate Presentation

Evogene Earnings Call Transcript: Q3 2024

Nov 21, 2024, 9:00 AM EST - 1 year ago

Evogene Earnings Call Transcript: Q3 2024

Evogene Quarterly report: Q3 2024

Nov 21, 2024, 9:00 AM EST - 1 year ago

Evogene Quarterly report: Q3 2024

Evogene Reports Third Quarter 2024 Financial Results

Nov 21, 2024, 7:30 AM EST - 1 year ago

Evogene Reports Third Quarter 2024 Financial Results

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Nov 19, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Nov 12, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Evogene Schedules Third Quarter 2024 Financial Results Release

Nov 7, 2024, 7:00 AM EST - 1 year ago

Evogene Schedules Third Quarter 2024 Financial Results Release

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Evogene Registration statement: Registration Filing

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Evogene Registration statement: Registration Filing

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Aug 23, 2024, 8:55 AM EDT - 2 years ago

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Evogene Earnings Call Transcript: Q2 2024

Aug 22, 2024, 9:00 AM EDT - 2 years ago

Evogene Earnings Call Transcript: Q2 2024

Evogene Earnings release: Q2 2024

Aug 22, 2024, 9:00 AM EDT - 2 years ago

Evogene Earnings release: Q2 2024

Evogene Reports Second Quarter 2024 Financial Results

Aug 22, 2024, 7:00 AM EDT - 2 years ago

Evogene Reports Second Quarter 2024 Financial Results

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Aug 12, 2024, 7:11 AM EDT - 2 years ago

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

ikerrr
ikerrr Jul. 21 at 5:32 PM
$EVGN Looks Like a proxy fight, thats never good short term . Typical bullshit selling at 40 cent ATM prices for AI Tech Pharma crazy. I say get rid of them all, Firesale this POS for $3 ashare or we're looking at R/S. Its they're fault we're at this point F em
0 · Reply
FinacialSuicide
FinacialSuicide Jul. 21 at 1:11 AM
$EVGN
0 · Reply
StockScanners
StockScanners Jul. 18 at 8:33 AM
$EVGN keep watch if this holds above .60
0 · Reply
FinacialSuicide
FinacialSuicide Jul. 17 at 4:25 PM
$EVGN wants to fly higher!
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 17 at 2:26 PM
$EVGN hourly breakout
0 · Reply
suntanner20
suntanner20 Jul. 17 at 11:38 AM
$EVGN Activist investor Silberman took a 1.6m -1.9m stake in Evogene and wants to replace 3 board members with his own people. Incredibly, he wants to keep Ofer Haviv, CEO. The stake is over 10% so he cant sell without filing and if he sells he cant keep profits This stock should scream to 1.25 per share ( armistice 5m warrant price). The float is tight. The validation of Evogene's ChemPass AI should be at record highs for them and industry Pharma ag and tech companies are surrounding it. AI Drug discovery engines are IPOing at 1-2 billion per company. This engine is a 100-200m engine today but being totally mishandled by CEO and board in their capital structure dealings with Armistice and banker AGP. We should be trading at 10 now not .58 that said, the valuation with all the games should be 1.25 Activist if bad actor will take company over and sell chempass for 100m and place new company in shell. If good actor, he'll find a way to drive value in chempass and drive share price up
0 · Reply
StockScanners
StockScanners Jul. 17 at 4:51 AM
$EVGN reached .60
0 · Reply
FinacialSuicide
FinacialSuicide Jul. 16 at 2:47 PM
$EVGN wants to fly! We need help!
0 · Reply
StockScanners
StockScanners Jul. 16 at 4:20 AM
$EVGN keep watch if this holds above .49
0 · Reply
MrTicker
MrTicker Jul. 15 at 11:38 AM
$EVGN Evogene's AgPlenus Subsidiary Introduces Antifungal Potency Predictor BENZINGA 6:33 AM ET 7/15/2026 AgPlenus Ltd., a company developing novel, sustainable crop protection products and a subsidiary of Evogene Ltd.(EVGN) , today announced the launch of its Antifungal Potency Predictor (APP). This new machine learning model predicts the antifungal potency of small molecules directly from their chemical structures, expanding the capabilities of Evogene's(EVGN) ChemPass AI for Ag™ platform by forecasting biological efficacy prior to chemical synthesis and fungal assay validation.
0 · Reply
FinacialSuicide
FinacialSuicide Jul. 15 at 11:33 AM
$EVGN
0 · Reply
MrTicker
MrTicker Jul. 15 at 11:33 AM
$EVGN AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities PR NEWSWIRE 6:30 AM ET 7/15/2026
0 · Reply
WuTangMane
WuTangMane Jul. 10 at 7:50 PM
$EVGN people rather be in than out for the weekend news to spread. Tic tok tic tok
0 · Reply
MrTicker
MrTicker Jul. 10 at 1:29 PM
$EVGN updated 13D Form SCHEDULE 13D Evogene Ltd. Filed by: L.I.A. Pure Capital Ltd 10K WIZARD 8:27 AM ET 7/10/2026 http://archive.fast-edgar.com/20260710/A322OQ2CLZ22LZ7V22ZL2ZY25PTVW222Z286 Filed on: July 10, 2026
1 · Reply
WuTangMane
WuTangMane Jul. 10 at 12:46 PM
$EVGN in and loading heavy at market close today. This runs hard monday into next week.
0 · Reply
Abcsam
Abcsam Jul. 10 at 7:29 AM
$EVGN watching this one
0 · Reply
DayTrade_4Life
DayTrade_4Life Jul. 10 at 7:17 AM
💵Some Stocks to Watch for 10 July: ELPW GMM WOK ELAB SDOT $JLHL $SCNX $CIRC $WRAP $EVGN 💪Below are results from yesterday and this month's Top Alerts. 👉See profile to Join Us.
0 · Reply
FinacialSuicide
FinacialSuicide Jul. 10 at 1:36 AM
$EVGN looking for the dollar land!
0 · Reply
topstockalerts
topstockalerts Jul. 9 at 11:38 PM
$EVGN this one’s acting different today… in a good way
0 · Reply
omenkes
omenkes Jul. 9 at 7:51 PM
$EVGN https://finance.yahoo.com/healthcare/articles/insilico-initiates-phase-iii-clinical-134300992.html - an AI designed molecule entering phase 3. the decision to advance AFTER phase 2 results is an affirmation for the whole field. https://allsci.com/news/licensing-deals/evogene-pairs-chempass-ai-with-tel-aviv-university-to-accelerate-academic-drug-discovery-pipeline/ - read carefully. what it says is that the Ramot and the innovation establishment of Israel will use Chempass AI to advance the projects that are selected by them for advancement to move them towards clinical trials. thats a big deal. thats a lot of trust and volume. Ramot is the Tel Aviv university commercialization branch. they are the biggest in biology. Weitzman should be also not far away (home turf...).
0 · Reply
BioTuesdays
BioTuesdays Jul. 9 at 5:55 PM
$EVGN and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating from Israeli academic research. https://biotuesdays.com/2026/07/09/evogene-and-bcdd-collaborate-in-drug-discovery-initiative/
0 · Reply
PantyRaid
PantyRaid Jul. 9 at 5:28 PM
$EVGN already below what it opened at. If youre Lucky shorts won't tank it to .30s
0 · Reply